Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Superfluid Dx, Inc. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, the portfolio has 1 pending office action, which represents the volume of active prosecution for the company. This action is being reviewed by 1 distinct examiner, meaning the immediate success in securing patent rights is tied to the specific scrutiny of a particular individual. This level of concentration reflects the current prosecution pipeline for Superfluid Dx, Inc.
The company's filings are currently restricted to the distinct art unit. HOPPE, EMMA RUTH is the busiest examiner for Superfluid Dx, Inc., holding the busiest examiner pending office action. As this is the pending action in the portfolio, the examiner's expertise and past behavior in the Biotechnology & Pharmaceuticals field are the primary variables for the near-term prosecution outcomes. The data reflects the targeted approach to intellectual property within the technical and administrative domain for Superfluid Dx, Inc.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HOPPE, EMMA RUTH | 1 | 42.1% | +56.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17932244 | SYSTEMS AND METHODS OF DETECTING A RISK OF ALZHEIMER'S DISEASE USING A CIRCULATING-FREE MRNA PROFILING ASSAY | HOPPE, EMMA RUTH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17932244 | SYSTEMS AND METHODS OF DETECTING A RISK OF ALZHEIMER'S DISEASE USING A CIRCULATING-FREE MRNA PROFILING ASSAY | HOPPE, EMMA RUTH | — |
| Art Unit | Apps |
|---|---|
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17932244 | SYSTEMS AND METHODS OF DETECTING A RISK OF ALZHEIMER'S DISEASE USING A CIRCULATING-FREE MRNA PROFILING ASSAY | HOPPE, EMMA RUTH | 1683 | §101§103§112 | Non-Final OA | — | Pending | Sep 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial